Salute e Benessere

Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems…

The new cobas 6800/8800 systems 2.0 enhances throughput, run flexibility, enables sample prioritisation and is available as an upgrade to existing systems in healthcare settings around the world.Laboratories can now perform a wider range of tests on a single solution, simplifying laboratory logistics and helping to optimise the use of resources.Basel, 13 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE certification of the new cobas® 6800/8800 systems 2.0...
Nasdaq GlobeNewswire
13/12/2024

Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA…

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosisDesignation is based on positive results from the HERCULES study in adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS)Tolebrutinib is the first and only brain-penetrant BTK inhibitor in MS to be designated Breakthrough Therapy by the FDA Paris, December 13, 2024.The US Food and Drug Administration (FDA) has granted Breakthrough Therapy...
Nasdaq GlobeNewswire
13/12/2024

Midea Strengthens Global Presence in the Heat Pump Industry with Optimistic…

Recognized as one of the 10 Breakthrough Technologies of 2024 by MIT Technology Review, heat pump technology is a pivotal innovation in reducing global reliance on fossil fuels and advancing carbon neutrality. Guan anticipates a strong market recovery over the next two years, driven by technological advancements, supportive policies, and increasing consumer awareness. Recognized asone of the 10 Breakthrough Technologies of 2024 by MIT Technology Review, heat pump technology is a pivotal...
PR Newswire
13/12/2024

Global Hematology Market to Exhibit Growth at a CAGR of ~8% by 2030 |…

Key Takeaways from the Hematology Market Report Key Takeaways from the Hematology Market Report To read more about the latest highlights related to the hematology market, get a snapshot of the key highlights entailed in theGlobal Hematology Market Report Hematology Overview Hematology is a specialized branch of medicine that focuses on the study, diagnosis, treatment, and prevention of blood-related disorders and diseases. It encompasses a wide range of conditions, including...
PR Newswire
12/12/2024

Innocan Pharma Provides its Annual "State of Research and Development" Update…

On the veterinary front, LPT-CBD's innovation was recognized by the FDA's Center for Veterinary Medicine (CVM), which granted Innocan a fee waiver for 2024 and issued a number that identifies an Investigational New Animal Drug (INAD). This designation allows Innocan to facilitate correspondence and data exchange with the CVM to support the development of LPT-CBD as a new veterinary drug. On the veterinary front, LPT-CBD's innovation was recognized by the FDA's Center for Veterinary Medicine...
PR Newswire
12/12/2024

Results of the votes of the Combined Shareholders' General Meeting of December…

Daix (France), New York City (New York, United States), December 11, 2024– Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the results of the votes of its Combined...
Nasdaq GlobeNewswire
12/12/2024

VelaLabs Announces Strategic Partnership with EarlyHealth Group to Support…

Under the agreement, EarlyHealth Group will manage the supply of clinical trial materials, packaging and labeling, logistics, and early access programs. VelaLabs will complement this offering with advanced characterization and quality control (QC) testing of biomolecules, delivering a complete package for sponsors and Contract Research Organizations (CROs). “This partnership with EarlyHealth Group aligns perfectly with VelaLabs' commitment to provide a comprehensive service platform to...
Nasdaq GlobeNewswire
12/12/2024

Penalty payment to a member of Orion's Board of Directors for delay in notifying…

ORION CORPORATIONSTOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 12 DECEMBER 2024 at 20.30 EET Penalty payment to a member of Orion's Board of Directors for delay in notifying managers' transaction In accordance with the applicable regulations, Orion Corporation discloses the following information:The Financial Supervisory Authority (FIN-FSA) has imposed a penalty payment of EUR 6,000 on Ari Lehtoranta, a member of the Board of...
Nasdaq GlobeNewswire
12/12/2024

FAAM-EUROBAT 2024 Concludes with Groundbreaking Advances in Food Allergy and…

ATHENS, Greece, Dec.12, 2024(GLOBE NEWSWIRE) --FAAM-EUROBAT 2024, held from 21-23 November at the InterContinental Athenaeum Athens, brought over 550 attendees from over 25 countries to share the latest advancements in food allergy and anaphylaxis research.The event featured impactful sessions, debates, workshops, and plenary discussions, highlighting new evidence and the importance of collaboration in tackling health challenges in food allergy and anaphylaxis.A standout...
Nasdaq GlobeNewswire
12/12/2024

EssilorLuxottica: EssilorLuxottica's greenhouse gas emissions reduction targets…

EssilorLuxottica's greenhouse gas emissions reduction targets validated by the Science Based Targets initiative (SBTi) Paris, France (12 December 2024)– EssilorLuxottica announced today that its near-term greenhouse gas (GHG) emissions reduction targets have been validated by the Science Based Targets initiative (SBTi), marking a key milestone in the Company's efforts to reduce the environmental impact across its entire value chain. The new 2030 targets address emissions across the...
Nasdaq GlobeNewswire
12/12/2024

Healthcare Executives Embrace Generative AI to Boost Patient Outcomes

The article continued: At Fortune'srecent Brainstorm AI conference in San Francisco, several healthcare executives voiced their expectation that the technology will transform the field. According to analysts at MarketsandMarkets Research, the Global AI in Healthcare Market is set to hit US$164.16 billion by 2030, growing at an explosive 49.1% CAGR. The article continued: At Fortune'srecentBrainstorm AI conference inSan Francisco, several healthcare executives voiced their expectation...
PR Newswire
12/12/2024

Structural Heart Devices Market to Hit USD 25.69 Billion by 2029 with 9.5% CAGR…

Browse in-depth TOC on "Structural Heart Devices Market"359 - Tables53 - Figures304 - Pages Browse in-depth TOC on "Structural Heart Devices Market" 359 - Tables 53 - Figures 304 - Pages Based on product, the Structural heart devices market is segmented into Heart Valve Devices, Occluders, Closure systems and Delivery systems, Annuloplasty rings, and accessories. The Heart valve devices are further segmented into transcatheter heart valves and surgical heart valves...
PR Newswire
12/12/2024

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and…

AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has granted Patent No. 2,032,813 — a compositions and methods patent — covering Ampligen ®(rintatolimod) for use in the treatment of the post-COVID condition of fatigue. The patent inventors, AIM CEO Thomas K. Equels and AIM Medical Officer David R. Strayer, M.D., have assigned the granted patent to the Company.AIM CEO Thomas K. Equels...
Nasdaq GlobeNewswire
12/12/2024

Coronado Research announce appointment of Dr. Jennifer Bradford as VP, Head of…

Coronado Research Chief Scientific Officer, Professor Jennifer Visser-Rogers said, "Jenny brings a wealth of experience in data science, and is expert in using AI and data science to help companies extract value from their data. She will support our vision of advancing pharmaceutical research through cutting-edge data-driven clinical trials that leverage emerging technologies to create a more effective and equitable model." Coronado Research Chief Scientific Officer…
PR Newswire
12/12/2024

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational…

- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts - Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, with 64.6% of patients achieving landmark 6-month PFS - Inupadenant + carboplatin/pemetrexed safety profile was manageable and tolerable, with no dose-dependent toxicity observed - Inupadenant...
Nasdaq GlobeNewswire
12/12/2024

Novo Nordisk A/S: European regulatory authority adopts positive opinion for an…

Bagsværd, Denmark, 12 December 2024– Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic ®(once-weekly subcutaneous semaglutide) label to reflect data from the FLOW kidney outcomes trial. The FLOW trial assessed the risk reduction from Ozempic ®therapy in chronic kidney disease-related events, including persistent ≥50% decline in estimated glomerular...
Nasdaq GlobeNewswire
12/12/2024

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology…

Company on track to deliver five Investigational New Drug (IND) applications as part of '5 by 5' solid tumor strategy 18 months ahead of original targetNomination of ZW209, a novel trispecific T cell engager, as fifth development candidate in the Company's solid tumor portfolioExpansion into autoimmune and inflammatory diseases (AIID) and hematology oncology leverages the Company's clinically validated Azymetric™ technology platform and expertise in multispecific therapeutics ...
Nasdaq GlobeNewswire
12/12/2024

Evaxion establishes new AI-derived precision cancer vaccine concept

Evaxion's AI-Immunology™ platform allows for the design of precision cancer vaccines targeting non-conventional ERV tumor antigens shared across patientsNovel preclinical data confirms the effectiveness of the precision vaccine approach by inducing strong T-cell responses and tumor growth inhibition in mice, thereby establishing preclinical Proof-of-ConceptThe approach could allow for a broader use of cancer vaccines, also for patients not responding to conventional immunotherapies ...
Nasdaq GlobeNewswire
12/12/2024

Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline…

Under the terms of the agreement, Synaffix is eligible to receive up to USD 368 million in upfront and clinical, regulatory, and commercial milestone payments, plus tiered royalties on net sales. Synaffix is responsible for manufacturing the components related to its proprietary technologies, and Elevation Oncology is responsible for the research, development, manufacturing, and commercialization of the ADC. Under the terms of the agreement, Synaffix is eligible to receive up toUSD 368...
PR Newswire
12/12/2024

BC Platforms-Nottingham Partnership to Power World-Leading University and…

New contract with the University of Nottingham and Nottingham University Hospitals NHS Trust to boost data capabilities, sharing, and innovation – accelerating dialogue and data sharing between clinicians and basic researchers to ultimately benefit patients.Part of a larger programme seeking to learn insights from other healthcare systems that could benefit patients in Nottingham – ensuring data security while enabling the sharing of trends and results with significant global relevance...
Nasdaq GlobeNewswire
12/12/2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic…

This combination is being evaluated in patients with advanced ER+/HER2- breast cancer that harbors ESR1 mutations, and who have experienced progression after standard first-line treatment. Results from the phase III EMERALD study were the basis for elacestrant's approval. Meanwhile, everolimus has shown efficacy in inhibiting other resistance mechanisms in this type of cancer. The elacestrant and everolimus combination has demonstrated preliminary efficacy with a manageable safety profile in…
PR Newswire
12/12/2024

COSRX Unveils The New Advanced Snail Mucin Glass Glow Hydrogel Mask

The Advanced Snail Mucin Glass Glow Hydrogel Mask is formulated with a high concentration of Snail Secretion Filtrate (Mucin) to deliver powerful all-in-one skincare benefits in a single use. Using innovative hydrogel technology, the mask gradually turns transparent as its active ingredients are absorbed into the skin, offering hydrating, brightening, soothing, and firming effects while improving overall skin texture and radiance. Uniquely, the mask can also be used overnight, making it ideal…
PR Newswire
12/12/2024

Neuraxpharm and Pharmathen enter into strategic co-development agreement to…

Under this agreement, Neuraxpharm will have exclusive rights to commercialise these therapies in Europe, and in countries outside of Europe where the group has a direct presence, while Pharmathen will have exclusive rights for North America and all other countries not covered by Neuraxpharm. Under this agreement, Neuraxpharm will have exclusive rights to commercialise these therapies inEurope, and in countries outside ofEuropewhere the group has a direct presence, while Pharmathen will...
PR Newswire
12/12/2024

General Inception acquires Enable Medicine and announces strategic partnership…

Power of generative biological search Power of generative biological search Enable Medicine harnesses the revolutionary capabilities of AI to guide novel insights into biology and medicine. The platform unlocks the power of generative biological search, which uses cutting-edge AI models to search maps of disease for novel drug targets and indications. The approach prioritizes indexing high quality multimodal cellular data to enable the research community and pharmaceutical industry to...
PR Newswire
12/12/2024
Altri  Comunicati